

## EXHIBIT A

Name : Cefuroxime Axetil  
 Innovator : Glaxo  
 Format : Tablet 125/250/500 mg, Suspension 125/250 mg  
 RM Suppliers : Accord, bpC, Ranbaxy, Aurebindo

### MARKET DATA (MSI)\*

1998 sales	1999 sales	Growth
P 494,350,375	P 560,022,765	13%

\* Includes sodium Cefuroxime injection.

### PRELIMINARY COSTING

Format	Innovator	Unilab 30% COG	Unilab 40% COG
Tablet	P 57/ 250 mg	P 63.20	P 47.48
Suspension	P 300/50 ml (125 mg)	NA	NA

### PATENT STATUS

Patent	Remark	Patent Expiry
Axetil	Ester derivatives	MY 12/31/2001
Amorphous form	Amorphous form is the bioavailable form	MY 12/31/2004
and Process		SG 7/15/2005
Suspension	Composition patent: lipid coating for taste masking	PP 1/29/2009
		MY 7/31/2010
		SG 8/23/2008
Tablet	Composition patent: thin film coating for rapid release	PP 9/18/2008
		MY 4/30/2009
		SG 10/26/2007

### COMMENTS

Sodium Cefuroxime used in the injection format is poorly absorbed when used orally. Cefuroxime Axetil, an ester of Cefuroxime, is a prodrug with good bioavailability. The commercial Cefuroxime Axetil is in amorphous form. Composition patent for suspension can be circumvented by using non-lipid coating. First step is to look for supplier who can sell us non-infringing coated granules; if not available, develop locally. Composition patent for tablet is with thin film coating; can circumvent if we use capsule format or tablet without film coating, or tablet inside a capsule?

4/23/2000

*Nikam T. S. Thakur*